Company intelligence / Profile preview
Vogenx
Durham, North Carolina, United Statesvogenx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Vogenx has completed a Phase 2 clinical study of mizagliflozin for post-bariatric hypoglycemia (PBH) with positive results announced in June 2023. The company initiated another Phase 2 clinical study for mizagliflozin in PBH in August 2023.
- Therapeutic areas
- GastroenterologyEndocrinology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Vogenx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vogenx.